Epibrassinolide (EBR; B1105; 24-Epibrassinolide) is a biologically active compound of the brassinosteroids, steroid-derived plant growth regulator family; was shown as a potential apoptotic inducer in various cancer cells without affecting the non-tumor c

EPI-743 (Vatiquinone,EPI-589) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone.

EphB3-IN-1 is the first potent, selective inhibitor of EphB3 that exhibits inhibiting EphB3 autophosphorylation in cells with IC50 of 3 nM.

Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.

EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor with increased aqueous solubility and greater cellular Usp9x inhibitory activity than WP1130.

Enzaplatovir (BTA-585, BTA-C585) is an orally bioavailable RSV fusion protein inhibitor for the treatment of respiratory syncytial virus infections..

Enviroxime (Zinviroxime.

Entecavir is a deoxyguanosine nucleoside analogue with antiviral activity against the hepatitis B virus (HBV).

Enocitabine is an anti-tumor agent and an antineoplastic. A derivative of Cytarabine.

Enalapril maleate (Vasotec)

Enadoline (CI 977.

EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities.

EML-405 (EML405) is a small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 14 uM.

Emixustat, a novel visual cycle modulator, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro.

EMD534085 is a kinesin inhibitor currently in clinical development.

EMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over AT1 receptor, produces analgesia in rodent model of neuropathic pain..

Elubrixin (SB-656933, GSK-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist.

Elocalcitol

ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease.

Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist.

Elaiophylin (Gopalamicin.

eIF4A3 inhibitor 53a is a potent, selective and cell-active eukaryotic initiation factor 4A3 (eIF4A3) inhibitor with IC50 of 0.26 uM, SPR Kd of 43 nM.

EHT 5372 is a novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.

Eggmanone is a potent, selective inhibitor of PDE4 with (IC50=72 nM) that antagonizes the Hedgehog signaling pathway.

EGF816 (Nazartinib) is a potent, irreversible, mutant-selective EGFR inhibitor with Ki and Kinact of 31 nM and 0.222 min-1, respectively.

Eg5 Inhibitor V, trans-24 is a potent and specific Eg5 inhibitor with an IC50 of 0.65 μM, and can be used in the research of cancer.

EG01377 is a potent and bioavailable inhibitor of the NRP1/VEGF-A interaction (Kd=1.32 uM), selective for NRP1 over the closely related protein NRP2.

EG00229 is a specific inhibitor of neuropilin-1 (NRP1)/VEGF-A interaction, inhibits the binding of biotinylated VEGFA to NRP1 with IC50 of 8 uM.

eFT226 is a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies, promotes eIF4A binding to specific mRNA sequences and interferes with the assembly of the eIF4F initiation complex.